Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3... by Matasar, Matthew J, MD, Capra, Marcelo, MD, Özcan, Muhit, Prof, Lv, Fangfang, MD, Li, Wei, Prof, Yañez, Eduardo, MD, Sapunarova, Katya, PhD, Lin, Tongyu, Prof, Jin, Jie, Prof, Jurczak, Wojciech, Prof, Hamed, Aryan, MD, Wang, Ming-Chung, MD, Baker, Ross, Prof, Bondarenko, Igor, Prof, Zhang, Qingyuan, Prof, Feng, Jifeng, Prof, Geissler, Klaus, Prof, Lazaroiu, Mihaela, MD, Saydam, Guray, Prof, Szomor, Árpád, MD, Bouabdallah, Krimo, MD, Galiulin, Rinat, MD, Uchida, Toshiki, MD, Soler, Lidia Mongay, MD, Cao, Anjun, PhD, Hiemeyer, Florian, MSc, Mehra, Aruna, MD, Childs, Barrett H, MD, Shi, Yuankai, Prof, Zinzani, Pier Luigi, Prof

Get full text

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicent... by Dimopoulos, Meletios A, Prof, Moreau, Philippe, Prof, Palumbo, Antonio, Prof, Joshua, Douglas, Prof, Pour, Ludek, Prof, Hájek, Roman, Prof, Facon, Thierry, Prof, Ludwig, Heinz, Prof, Oriol, Albert, Prof, Goldschmidt, Hartmut, Prof, Rosiñol, Laura, Prof, Straub, Jan, Prof, Suvorov, Aleksandr, Prof, Araujo, Carla, Prof, Rimashevskaya, Elena, Prof, Pika, Tomas, Prof, Gaidano, Gianluca, Prof, Weisel, Katja, Prof, Goranova-Marinova, Vesselina, Prof, Schwarer, Anthony, Prof, Minuk, Leonard, Prof, Masszi, Tamás, Prof, Karamanesht, Ievgenii, Prof, Offidani, Massimo, Prof, Hungria, Vania, Prof, Spencer, Andrew, Prof, Orlowski, Robert Z, MD, Gillenwater, Heidi H, MD, Mohamed, Nehal, PhD, Feng, Shibao, PhD, Chng, Wee-Joo, Prof

Get full text